LONDON, Jan. 13 /PRNewswire/ -- CRC Development Ltd (CRC) announced today
that it has acquired the business and assets of Premier Research from SCP
This is the third acquisition CRC (formerly ACSC) has made within 2 years
and forms part of CRC's strategic plan to achieve a rapid, global presence in
the contract clinical research market.
Dr Simon Yaxley, CEO of CRC, says, "Our first acquisition in May 2002 was
Therapeutic Management which gave us a presence in the UK and the USA. Then
in May 2003 we acquired CRC GmbH, a company operating throughout Western,
Central and Eastern Europe plus Scandinavia and Israel. Our next step was to
strengthen significantly our presence in the US market and Premier Research
represented the ideal opportunity. Following the experience of the last
merger, we are confident that Premier's operations will rapidly integrate with
the CRC family and will significantly add to our clinical and operational
"We are proud of the fact that within 2 years we have built an
International company that boasts excellent staff, a wide ranging and loyal
customer base, and a solid business backlog of more than US$35 million."
Mr Will Passano, CEO of SCP Communications, Inc., the former owner of
Premier Research, adds, "This is truly a win/win for both companies. The fit
between CRC and Premier is a good one, not only from a business perspective,
but also styles and personalities."
CRC will continue to develop its reputation as a world-class CRO with
particular strengths in the areas of Oncology, CNS and Immunology. The
Company has a very strong medical and scientific base, which provides
significant expertise and experience in the development of new drugs.
In addition to its strong presence and excellent reputation in North
America, Premier Research also provides fax and Internet data collection
systems, which will complement the Oracle Clinical Data Management systems of
SOURCE CRC Development Ltd